万孚生物(300482) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥83,661,000.50, representing a year-on-year increase of 38.58%[8] - Operating revenue for the period was ¥456,274,202.76, up 29.45% from the same period last year[8] - The net profit after deducting non-recurring gains and losses was ¥87,809,038.20, reflecting a 53.71% increase year-on-year[8] - Basic earnings per share increased to ¥0.25, a rise of 31.58% compared to the same period last year[8] - The company's total equity attributable to shareholders reached ¥2,143,595,112.58, compared to ¥1,953,834,023.75 in the previous year, marking a growth of 9.7%[51] - Net profit attributable to the parent company increased to ¥875,313,160.78, compared to ¥664,521,624.35 in the same period last year, reflecting a growth of 31.7%[51] - The company's total comprehensive income for the current period was ¥93,031,855.58, compared to ¥66,627,215.26 in the previous period, marking a 39.7% increase[59] - The total profit for the current period was ¥76,895,694.61, an increase of 86.5% from ¥41,195,297.32 in the previous period[63] - The company's operating profit for the current period was ¥75,451,880.04, an increase of 76.8% from ¥42,718,271.47 in the previous period[63] - The net profit for the current period was ¥69,170,239.75, up 73.2% from ¥39,899,101.12 in the previous period[66] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,829,163,930.22, an increase of 5.12% compared to the end of the previous year[8] - Total liabilities decreased to ¥486,141,851.29 from ¥540,011,576.14, indicating a reduction in the company's debt levels[38] - Total assets increased to ¥2,829,163,930.22 from ¥2,691,461,368.16, showing overall growth in the company's asset base[35] - Total liabilities of the company increased to ¥354,490,217.35 from ¥309,810,096.17, reflecting a rise of 14.4%[48] - Total assets amounted to approximately $2.69 billion, remaining stable compared to the previous year[99] - The total liabilities were approximately $523.62 million, consistent with the previous year's figures[102] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥135,264,219.30, a significant increase of 152.78%[8] - Cash inflows from operating activities totaled approximately ¥1.49 billion, up from ¥1.22 billion in the previous period, indicating a growth of about 22%[86] - The net cash flow from operating activities was approximately ¥135.26 million, a substantial increase from ¥53.51 million in the previous period[88] - Cash inflow from operating activities totaled approximately $876.83 million, an increase from $696.74 million year-over-year, representing a growth of about 25.8%[92] - Cash inflow from investment activities reached approximately $2.89 billion, significantly higher than $824.87 million in the previous year, marking an increase of about 250%[92] - Cash inflows from financing activities totaled approximately ¥144.41 million, down from ¥849.70 million in the previous period, indicating a decrease of about 83%[89] Investments and Expenses - Research and development expenses for the period were ¥41,650,950.64, up from ¥31,349,212.85, indicating a focus on innovation and product development[52] - Research and development expenses increased to ¥113,035,261.27, compared to ¥87,138,984.77 in the previous period, marking a 29.7% rise[70] - The company reported a significant increase in cash received from investment recoveries, totaling approximately $2.87 billion, compared to $823.10 million in the prior year[92] - The company achieved an investment income of ¥21,932,782.74, a substantial increase from ¥3,187,161.02 in the previous period[80] Shareholder Information - The company reported a total of 9,101 shareholders at the end of the reporting period[12] - The top ten shareholders collectively held 38.87% of the company's total shares[12] - The company repurchased 903,177 shares, accounting for 0.26% of total share capital, at a total cost of ¥30,185,940.64[24]